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Introduction 
Programmed cell death receptor 1 inhibitors (anti-
PD-1) have been proven to be beneficial in treating 
several solid cancers, such as melanoma, renal cell 
carcinoma, non-small cell lung cancer, and 
squamous cell carcinoma of the head and neck [1]. 
The binding of PD-1 with its ligand (PD-L1) 
downregulates cytotoxic lymphocyte activity [2]. 
Programmed cell death ligand 1 is overexpressed in 
these tumors as a means of evading the immune 
system's response against them. Anti-PD-1 works by 
blocking this interaction. However, this immune 
response modulation is not tumor-specific, which 
explains why these medications may be associated 
with immune-related adverse events (irAE), [1, 3-5]. 
Cutaneous irAE are among the most common, 
appearing in up to 50% of patients [4, 5]. Several 
types of dermatologic irAE have been described, 
particularly vitiligo and lichenoid dermatitis, which 
has been reported with different cutaneous and 
mucosal presentations [1, 3, 4, 6]. However, these 
lichenoid reactions are yet to be fully characterized 
and the relationship with tumor response is still 
unclear [1, 2]. We present a case of digital ulcerative 
lichenoid dermatitis in a patient receiving 
pembrolizumab for squamous cell carcinoma of the 
oral mucosa. 
 
Case Synopsis 
A 77-year-old male consulted our clinic for a painful 
digital lesion. He had a history of verrucous 
squamous cell carcinoma of the oral mucosa. After 
Abstract 
Programmed cell death receptor 1 inhibitors (anti-
PD-1) constitute a form of immunotherapy for the 
treatment of several cancers. They are associated 
with cutaneous immune-related adverse events 
(irAE), occurring in up to 50% of patients. Lichenoid 
dermatitis is frequent and several presentations have 
been described. Although attempts have been made 
to study these reactions, they are yet to be fully 
characterized and the relationship with tumor 
response is unclear. We describe a case of digital 
ulcerative lichenoid dermatitis resembling ulcerative 
cutaneous lichen planus that occurred during 
pembrolizumab therapy for oral squamous cell 
carcinoma. The patient developed a painful ulcer on 
his index finger 18 months into therapy. Biopsy 
revealed epidermal ulceration with intense lichenoid 
dermatitis. Immunohistochemical study revealed 
intense CD8 positivity at the ulcer’s edges and 
marked CD163 positivity at its base. Although 
idiopathic forms of this type of lichenoid dermatitis 
are particularly recalcitrant, our case was successfully 
managed with topical therapy and oncologic 
treatment did not require modification. One year 
after ending treatment the patient remains free of 
disease progression. It is unclear if this reaction is 
associated with his favorable oncologic response. 
This report adds an undescribed reaction to the 
increasing diversity of cutaneous irAE associated 
with anti-PD-1 therapy. 
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radical surgery, radiotherapy, and chemotherapy 
(cisplatin), he presented with lymph node metastasis 
and was started on pembrolizumab, 200mg every 
three weeks. After 18 months (25 cycles) he 
developed an intensely painful lesion that persisted 
for over two months despite topical antibiotic and 
zinc oxide ointment. He had no personal or familial 
history of dermatoses. 
Physical examination revealed an ulcerated, 
indurated ulcer on the medial and palmar aspect of 
his right index finger (Figure 1). The lesion had a 
fleshy, exudative floor and hyperkeratotic borders. 
There were no other relevant findings. 
Punch biopsy showed full-thickness epidermal 
ulceration and a dense lymphohistiocytic infiltrate 
with lichenoid disposition (Figure 2A). The 
epidermis on the borders showed marked 
orthokeratotic hyperkeratosis, irregular saw-tooth 
acanthosis, and secondary subepidermal clefting. 
Eosinophilic cytoid bodies were present in the 
papillary dermis, especially on the ulcerated portion. 
Immunohistochemical study showed intense 
positivity for CD8 lymphocytes with scattered 
exocytosis (Figure 2B) and CD163 histiocytes 
(Figure 2C), with milder positivity for CD3, CD4, 
CD68, and PD-L1. 
Treatment was started with daily application of 
topical betamethasone dipropionate 0.5% and 
gentamycin sulfate 1% cream, and zinc oxide 16.6% 
water-based ointment. The lesion improved 
significantly after three weeks and completely 
resolved after three months. Although he required 
occasional re-treatments for milder recurrences 
during the following three months, there was no 
need for pembrolizumab discontinuation or dose 
reduction. Thereafter, the patient received 10 more 
cycles and one year after completing 
pembrolizumab therapy he remains free of disease 
progression. 
 
Case Discussion 
The spectrum of anti-PD-1-associated cutaneous 
irAE is wide and broadens every day. Pruritic rash, 
vitiligo, and lichenoid dermatitis are among the most 
frequent [1, 3, 4]. Efforts have been made to study the 
profiles of both vitiligo and lichenoid dermatitis, as 
Figure 1. Digital ulcerative lichenoid dermatitis associated with 
pembrolizumab therapy. Indurated ulcer with keratotic borders 
on the medial and palmar aspect of the right index finger. 
Figure 2. Digital ulcerative lichenoid dermatitis associated with pembrolizumab therapy. A) Biopsy showing full-thickness epidermal 
ulceration. An underlying dense lichenoid lymphohistiocytic infiltrate is observed. Eosinophilic cytoid bodies are present in the papillary 
dermis at the base of the ulcer. The edges show hyperorthokeratosis, irregular acanthosis, and subepidermal clefting. H&E, 4×. B) CD8. 
Intense positivity for CD8 at the edges of the ulcer coupled with scattered exocytosis, 4×. C) CD163 immunohistochemistry. Intense 
positivity for CD163 at the base of the ulcer, 4×. 
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they seem to have different clinical and histological 
characteristics from their non-drug-related 
presentations [6-8]. To the best of our knowledge, 
there have been no reports of anti-PD-1-associated 
digital ulcerative lichenoid dermatitis resembling 
ulcerative cutaneous lichen planus (UCLP). 
Certain issues arise when a patient under anti-PD-1 
therapy presents with a skin reaction. Ideally, 
treatment for irAE should not interfere with the 
patient's antineoplastic treatment, making certain 
systemic therapies suboptimal. Fortunately, most 
cutaneous irAE are manageable with topical 
treatment [1, 4, 7]. Furthermore, reactions that might 
be life-threatening must be promptly recognized, as 
they would justify immunotherapy discontinuation. 
On the contrary, unnecessary anti-PD-1 suspension 
or dose reduction should be avoided as they could 
hinder the cancer treatment. 
Multiple types of lichenoid dermatitis in patients 
undergoing anti-PD-1 therapy have been reported. 
Some presented with palmar or plantar lichenoid 
papules and others with oral or genital erosions [1, 3, 
4, 6]. However, UCLP-like irAE have not been 
described. Owing to the clinical features and delayed 
presentation of our patient's irAE, metastatic disease 
was considered in the differential diagnosis. 
Histopathological examination ruled out malignancy 
and indicated grade 2 irAE instead. Despite the fact 
that idiopathic forms of UCLP are known to be 
recalcitrant to both topical and systemic therapy and 
that persistent painful lesions might motivate 
immunotherapy suspension [9], our patient's irAE 
was manageable with topical therapy and without 
modification of pembrolizumab therapy. 
Histologically, anti-PD-1-associated rashes are 
characterized by predominantly lymphocytic 
infiltrates with lichenoid disposition [7]. Schaberg et 
al. [7] compared histological and immunohisto-
chemical characteristics of anti-PD-1-associated and 
non-drug-related lichenoid dermatitis. The former 
showed more prominent spongiosis; in addition, 
epidermal necrosis was observed with greater 
frequency. Immunohistochemically, they only 
differed in the presence of CD163 histiocytes, which 
was significantly higher in lesions associated with 
anti-PD-1. This could be a reactive response to  
greater epidermal destruction or a contribution to 
the inflammatory reaction secondary to a M2-to-M1 
macrophage polarization switch derived from PD-1 
pathway blockade [7]. In our case, 
immunohistochemical study showed intense 
positivity of CD163 histiocytes at the base of the 
ulcer with a decrease on the edges where the 
epidermis was still preserved. We also observed a 
comparatively milder positivity for CD68 
macrophages. On the contrary, CD8 lymphocyte 
marking was predominant on the edges of the ulcer 
and less intense at its base. 
The PD-1 pathway, as a mechanism for keeping 
cytotoxic lymphocytes from reacting against self-
antigens, seems to be implicated in epidermal 
integrity preservation during inflammatory skin 
reactions [2]. In the context of anti-PD-1 therapy, 
these reactions have a prominent cytotoxic profile, 
exhibiting significant accumulation of CD8 
lymphocytes in the dermoepidermal junction with 
accompanying exocytosis and marked keratinocyte 
apoptosis [2]. Our patient's ulcerated plaque 
exhibited marked CD8 polarization of the lichenoid 
infiltrate, scattered exocytosis of CD8 lymphocytes, 
and abundant epidermal necrosis. This depicts an 
intense cytotoxic reaction against self-antigens 
present on the patient's keratinocytes and suggests 
it is secondary to blockade of PD-1-mediated 
immune downregulation. Since our patient was 
started on pembrolizumab for squamous cell 
carcinoma of the oral mucosa, this could reflect 
cross-reactivity between shared epidermal antigens 
present both on the primary tumor's cells and on 
epidermal cells on his finger. If so, this irAE could be 
associated with the favorable response to treatment, 
as he maintains progression-free-survival one year 
after completion. Analogously, a correlation 
between anti-tumor response and development of 
vitiligo as irAE in patients receiving anti-PD-1 for 
melanoma was reported [10]. 
 
Conclusion 
Cutaneous irAE in patients undergoing anti-PD-1 
therapy are common and increasingly diverse. This 
report adds an undescribed reaction that may 
simulate metastatic disease; management was 
surprisingly successful with topical treatments. 
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Further studies of these reactions are required to 
improve patient management and perhaps find a 
potential use as predictor of treatment response [1, 2, 5]. 
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